(Q50157070)

English

Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?

scientific article published on 2 June 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

3

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

author name string

Lu CY

1

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

Williams KM

2

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

publication date

2 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

Internal Medicine Journal

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

37

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

9

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

601-606

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01396.X

21 January 2018

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01396.X

21 January 2018

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01396.X

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01396.X

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01396.X

21 January 2018

Access to high cost drugs in Australia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01396.X

21 January 2018

What are the goals and principles of management in the early treatment of rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01396.X

21 January 2018

Changes in use of disease-modifying anti-rheumatic drugs in Australia over the period 1992-2004.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01396.X

21 January 2018

The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01396.X

21 January 2018

Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01396.X

21 January 2018

Identifiers

10.1111/J.1445-5994.2007.01396.X

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/17542999

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50157070&oldid=1229525749"